EUVIMEDEUVIMED entdecken
Crossref

Belimumab: Where Are We Three Years After FDA Approval?

Daniel J. Wallace

Current Treatment Options in Rheumatology · 2015

DOI: 10.1007/s40674-014-0001-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Treatment Options in Rheumatology, 2015. Verfasst von Daniel J. Wallace. Die Arbeit nennt 33 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Wallace, D. J. (2015). Belimumab: Where Are We Three Years After FDA Approval?. Current Treatment Options in Rheumatology. https://doi.org/10.1007/s40674-014-0001-4

Vancouver

Wallace DJ. Belimumab: Where Are We Three Years After FDA Approval?. Current Treatment Options in Rheumatology. 2015. doi:10.1007/s40674-014-0001-4

BibTeX
@article{Wallace2015,
  author = {Wallace, Daniel J.},
  title = {Belimumab: Where Are We Three Years After FDA Approval?},
  journal = {Current Treatment Options in Rheumatology},
  year = {2015},
  doi = {10.1007/s40674-014-0001-4}
}
Kostenlos starten →